novel complement component 2 and complement factor B protein (no standardized full name established)

This entry represents an annotated protein product from an uncharacterized transcript (ENSG00000244255), described as "novel complement component 2 (C2) and complement factor B (CFB) protein". It is provisionally classified as a putative serine protease based on Gene Ontology annotations but lacks experimental validation, clear protein evidence, or functional assignments in established resources. The annotation likely arises from automated prediction or cDNA similarity to established complement pathway genes (C2 and CFB), but the fusion of C2 and CFB identities is not supported by canonical gene structure or published biological data. There is no evidence this molecule is a distinct or functional entity beyond computational annotation, nor is it recognized as a receptor, therapeutic target, or biomarker. Current databases and literature do not recognize this as a validated clinical or drug target, and its inclusion may reflect a database artifact. Key issues: - The label "novel complement component 2 and complement factor B protein" conflates two separate and well-established proteins (C2 and CFB), which function independently in the complement pathway. - No experimental or peer-reviewed evidence confirms the existence or biological role of a fusion or novel protein encoded by ENSG00000244255. - For structured drug discovery, complement factor B (CFB) and complement component 2 (C2) should be considered as distinct targets with well-defined functions.

Other names

AL645922.1E7ETN3 proteinB4E1Z4 proteinUncharacterized protein highly similar to Complement factor B

Not established for any drug (no mechanistic data available for this target variant)